thoracic neoplasm,esophageal cancer,lung cancer
Conditions
Interventions
Experimental Group:Tetrandrine Injection shall be administered continuously for 6 days followed by 1 day of drug withdrawal, starting from the initiation of radiotherapy until the end of radiotherapy,
Control group:The placebo will be administered continuously for 6 days followed by a 1-day break, starting from the initiation of radiotherapy until its completion.
Sponsors
People's Hospital of Chongqin Hechuan
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Confirmed diagnosis of thoracic malignancy by pathology or cytology, and meeting the indications for thoracic radiotherapy. 2.Aged 18–75 years, with no restriction on gender. 3.Karnofsky Performance Status (KPS) score >=70, indicating the ability to tolerate radiotherapy and related treatments. 4.Patients voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with severe concurrent cardiac, hepatic, or renal insufficiency, or other serious underlying diseases. 2.Patients with allergies to tetrandrine or other related drugs. 3.Patients with a history of chronic lung diseases (such as chronic obstructive pulmonary disease, interstitial lung disease, etc.) that severely impair lung function. 4.Patients with a pulmonary infection within the past month. 5.Pregnant or lactating women. 6.Patients with poor compliance who are unable to cooperate with the completion of the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of radiation pneumonitis;Incidence of radiological pulmonary fibrosis; | — |
Countries
China
Contacts
Public ContactWang Guanliang
People's Hospital of Chongqin Hechuan
Outcome results
None listed